Angiogenesis-related factors are molecular targets for diagnosis and treatment of patients with esophageal carcinoma

Annals of Thoracic and Cardiovascular Surgery

Volumn 16, Issue 6, 2010, Pages 389-393

  Oshima, Yoko ^a   Yajima, Satoshi ^a   Yamazaki, Kunihiro ^a   Matsushita, Kazuyuki ^b   Tagawa, Masatoshi ^c   Shimada, Hideaki ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

BLOOD; ESOPHAGUS TUMOR; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); REVIEW;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ESOPHAGEAL NEOPLASMS; HEPATOCYTE GROWTH FACTOR; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-MET;

EID: 78751640261     PISSN: 13411098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Kitadai Y, Haruma K, Tokutomi T, Tanaka S, Sumii K, et al. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998; 4: 2195-200.
2. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000; 6: 1161-8.
3. Griffiths L, Stratford IJ. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy. Br J Cancer 1997; 76: 689-93.
4. Ren YJ, Zhang QY. Expression of midkine and its clinical significance in esophageal squamous cell carcinoma. World J Gastroenterol 2006; 12: 2006-10.
5. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Cancer 1997; 79: 206-13.
6. Igarashi M, Dhar DK, Kubota H, Yamamoto A, El-Assel O, et al. The prognostic significance of micro vessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer 1998; 82: 1225-32.
7. Takebayashi Y, Natsugoe S, Baba M, Akiba S, Fukumoto T, et al. Thymidine phosphorylase in human esophageal squamous cell carcinoma. Cancer 1999; 85: 282-9.
8. Oota M, Takeda A, Okazumi S, Matsubara H, Shimada H, et al. Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma. Oncol Rep 2002; 9: 23-8.
9. Barclay C, Li AW, Geldenhuys L, Baguma-Nibasheka M, Porter GA, et al. Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by co-expression of the FGF-2 antisense gene. Clin Cancer Res 2005; 11: 7683-91.
10. Zhang C, Fu L, Fu J, Hu L, Yang H, et al. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res 2009; 15: 4017-27.
11. Shimada H, Hoshino T, Okazumi S, Matsubara H, Funami Y, et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002; 86: 552-7.
12. Balasubramanian SP, Brown NJ, Reed MW. Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer 2002; 87: 1057-65. Review.
13. Bradbury PA, Zhai R, Ma C, Xu W, Hopkins J, et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 2009; 15: 4680-5.
14. Zhai R, Liu G, Asomaning K, Su L, Kulke MH, et al. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis 2008; 29: 2330-4.
15. Lurje G, Leers JM, Pohl A, Oezcelik A, Zhang W, etal. Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. Ann Surg 2010; 251: 857-64.
16. Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squamous cell carcinoma. Mutat Res 2009; 663: 52-9.
17. Shimada H, Takeda A, Nabeya Y, Okazumi S, Matsubara H, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001; 92: 663-9.
18. Kozlowski M, Kowalczuk O, Milewski R, Chyczewski L, Niklinski J, et al. Serum vascular endothelial growth factors C and D in patients with oesophageal cancer. Eur J Cardiothorac Surg 2010 Mar 10. [Epub ahead of print].
19. Tsirlis TD, Papastratis G, Masselou K, Tsigris C, Papachristodoulou A, et al. Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance? World J Gastroenterol 2008; 14: 2691-701.
20. Kimura H, Kato H, Tanaka N, Inose T, Faried A, et al. Preoperative serum vascular endothelial growth factor-C (VEGF-C) levels predict recurrence in patients with esophageal cancer. Anticancer Res 2008; 28: 165-9.
21. Futami R, Miyashita M, Nomura T, Makino H, Matsutani T, et al. Increased serum vascular endothelial growth factor following major surgical injury. J Nippon Med Sch 2007; 74: 223-9.
22. Shimada H, Takeda A, Shiratori T, Nabeya Y, Okazumi S, et al. Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma. Cancer 2002; 94: 1947-54.
23. Ying-Jia Ren, Qing-Yun Zhang. Expression of midkine and its clinical significance in esophageal squamous cell carcinoma. World J Gastroenterol 2006; 12: 2006-10.
24. Shimada H, Nabeya Y, Tagawa M, Okazumi S, Matsubara H, et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 2003; 94: 628-32.
25. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Kadomatsu K, et al. Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer. Oncol Rep 2003; 10: 411-4.
26. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 2002; 132: 41-7.
27. Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, et al. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004; 198: 737-41.
28. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, et al. Blockade of the vascular endothelial growth factor stress response increases the anti tumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-8.
29. Lin P, Sankar S, Dewhirst MW, Polverini PJ, Quinn TQ, et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Dif fer 1998; 9: 49-58.
30. Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, et al. Analysis of anti-proliferative and chemo sensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. Int J Cancer 2010; 127: 1197-208.
31. Homs MY, Voest EE, Siersema PD. Emerging drugs for esophageal cancer. Expert Opin Emerg Drugs 2009: 329-39. Review.
32. Fontaine E, McShane J, Page R, Shackcloth M, Mediratta N, et al. Aspirin and non-small cell lung cancer resections: effect on long-term survival. Eur J Cardiothorac Surg 2010; 38: 21-6.
33. Liu JF, Jamieson GG, Wu TC, Zhu GJ, Drew PA. A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. Ann Surg Oncol 2009; 16: 1397-402.
34. Ren Y, Cao B, Law S, Xie Y, Lee PY, et al. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res 2005; 11: 6190-7.
35. Tuynman JB, Lagarde SM, Ten Kate FJ, Richel DJ, van Lanschot JJ. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer 2008; 98: 1102-8.
36. Grugan KD, Miller CG, Yao Y, Michaylira CZ, Ohashi S, et al. Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc Natl Acad Sci U S A 2010; 107: 11026-31.
37. Matsumoto K, Nakamura T, Sakai K, Nakamura T. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4. Proteomics 2008; 8: 3360-70. Review.
38. Watson GA, Zhang X, Stang MT, Levy RM, Queiroz de Oliveira PE, et al. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia 2006; 8: 949-55.
39. Suzuki Y, Sakai K, Ueki J, Shimada H, Nakamura T, et al. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Int J Cancer 2010 Jan 26. [Epub ahead of print]
40. Shimada H, Ochiai T. Gene therapy for esophageal squamous cell carcinoma. Front Biosci 2008; 13: 3364-72. Review.